Neurocrine Biosciences, Inc.
NBIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeNeurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company carries a $17.18B market cap, placing it firmly in the large-cap category. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Market Cap
$17.18B
Beta
0.39
P/E (TTM)
26.37
P/E (Fwd)
13.47
EPS (TTM)
$6.48
EPS (Fwd)
$12.68
ROE
22.5%
ROA
11.6%
Cash
$1.32B
Total Debt
$463.5M
Free CF
$590.6M
52W Change
29.4%
Annual Financials
Cash vs Debt
With $1.32B in cash and $463.5M in debt, NBIX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $590.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 22.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.49B (2022) to $2.86B (2025), reflecting a 92% increase over the period.
NBIX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing NBIX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.